Jayesh Desai
The University of Melbourne · 611 works · 29,996 citations · h-index 68
Top works
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
- Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors
- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
- Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
- Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer
- SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)
- Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib Mesylate
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents